Evidence map›Paper›PMID 41969205›Full record

ReviewCancer control : journal of the Moffitt Cancer Center

The Role of Blood-Brain Barrier in Brain Cancer: From Pathophysiology to Therapeutic Approaches.

Diala El Masri, Maryam Tlayss, Lea El Masri, Hashem Shehade, Jana Al Achcar, Tarek Baroud, Tatiana Al Zakhem, Jad El Masri, Wassim Abou-Kheir

Abstract readReview
In one paragraph

Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Diala El MasriFaculty of Medicine, University of Balamand, Koura, Lebanon.
Maryam TlayssFaculty of Arts and Sciences, University of Balamand, Koura, Lebanon.
Lea El MasriFaculty of Arts and Sciences, University of Balamand, Koura, Lebanon.
Hashem ShehadeDepartment of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Jana Al AchcarFaculty of Medicine, Saint George University of Beirut, Beirut, Lebanon.ORCID 0009-0008-5302-8599
Tarek BaroudFaculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Tatiana Al ZakhemFaculty of Medicine, University of Balamand, Koura, Lebanon.
Jad El MasriNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.ORCID 0000-0001-6991-2508
Wassim Abou-KheirDepartment of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain tumors remain among the most lethal cancers, in part due to the limited ability of therapeutic agents to reach malignant cells protected by the blood-brain barrier (BBB). This specialized vascular interface preserves neural homeostasis through several mechanisms and different elements. In brain malignancies, the barrier may be disrupted, remodeled, or remain largely intact depending on tumor type, leading to highly variable effects on different therapeutic approaches. These challenges have driven the development of innovative delivery strategies, including molecular engineering, nanocarriers, receptor-mediated transport systems, focused ultrasound, and direct regional administration. Understanding BBB biology and its tumor-specific alterations is essential for designing effective therapeutic approaches capable of improving outcomes in brain cancer. Recent studies showed promising results with different approaches, including pharmacological approaches, nanotechnology-based approaches, physical disruption techniques, biological and cellular approaches, and convection-enhanced delivery. This review summarizes the current understanding of the role of BBB in brain cancer, and reviews emerging strategies to overcome this barrier and enable effective brain cancer therapy.

Indexed as

Antineoplastic AgentsBlood-Brain BarrierBrain NeoplasmsAnimalsDrug Delivery SystemsHumansAntineoplastic Agentsblood-brain barrierbrain cancerdrug propertiestherapeutic approaches

Identifiers

PMID41969205
PMCPMC13080181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.